Important note: Information in this article was accurate in 2006. The state of the art may have changed since the publication date.
|
|
AIDS Vol. 20; No. 15: P. 1961-1968 (10.03.06) - Friday, December 22, 2006
Matthew R. Golden; Thomas L. Gift; Devon D. Brewer; Mark Fleming; Matthew Hogben; Janet S. St. Lawrence; Hanne Thiede; H. Hunter Handsfield
From 2002 to 2005, 283 MSM peer recruiters were enrolled in a public health program in King County, Wash. Participants were recruited from an STD clinic, an HIV clinic, via media advertisements and through collaboration with community-based organizations (CBO). After undergoing a brief training, recruiters were paid $20 for each peer they referred for HIV, STD and viral hepatitis testing. Those who sought testing received $20. The main outcome measure was the number of new HIV cases identified and cost per case of HIV identified.
A total of 498 peers were referred for testing for HIV, STD and viral hepatitis. Among the 438 not previously diagnosed, 22 (5 percent) were HIV-positive, of whom 18 received their positive results. Researchers found other infections were variably present among those tested, including: gonorrhea [23/307 (8 percent)], chlamydia [6/285 (2 percent)], syphilis [1/445 (0.2 percent)], hepatitis C [61/198 (31 percent)], and surface antigen positive hepatitis B [8/314 (3 percent)]. Not including the costs of testing for viral hepatitis and STDs other than HIV, the cost per new HIV cases identified was $4,929. For the same period, the cost per new case of HIV identified via bathhouse-based HIV testing and through the county's largest CBO-based HIV testing program were $8,250 and $11,481, respectively.
"Peer referral is an effective means of identifying new cases of HIV among MSM," the authors concluded.
061222
AD062492
Copyright © 2006 - Information, Inc., Bethesda, MD. The CDC National Center for HIV, STD and TB Prevention provides the following information as a public service only. Providing synopses of key scientific articles and lay media reports on HIV/AIDS, other sexually transmitted diseases and tuberculosis does not constitute CDC endorsement. This daily update also includes information from CDC and other government agencies, such as background on Morbidity and Mortality Weekly Report (MMWR) articles, fact sheets, press releases and announcements. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC HIV/STD/TB Prevention News Update should be cited as the source of the information. Contact the sources of the articles abstracted below for full texts of the articles.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Elton John AIDS Foundation, the National Library of Medicine, AIDS Walk of Orange County, and donations from users like you.
Always watch for outdated information. This article first appeared in 2006. This material is designed to support, not replace, the relationship that exists between you and your doctor.AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2006. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.
.